Robert Michael Dudley - 14 Sep 2022 Form 4 Insider Report for Transcode Therapeutics, Inc. (RNAZ)

Role: Chief Executive Officer, Director, 10%+ Owner
Signature: /s/ Thomas A. Fitzgerald, as Attorney-in-Fact
Issuer symbol: RNAZ
Transactions as of: 14 Sep 2022
Net transactions value: +$23,000
Form type: 4
Filing time: 16 Sep 2022, 18:44:59 UTC
Previous filing: 01 Jun 2022
Next filing: 14 Dec 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RNAZ	Common Stock	Purchase	$23,000	+20,000	+2.3%	$1.15	893,114	14 Sep 2022	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.12 to $1.1761, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected.

Content

The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.12 to $1.1761, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected.